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Abstract
Background and Aims: Crohn’s disease-associated small bowel carcinoma is a rare event, usually 
reported to have a severe prognosis. However, in previous investigations we have found a 
minority of cases displaying a relatively favourable behaviour, thus outlining the need to improve 
the histopathological prediction of Crohn’s disease-associated small bowel carcinoma prognosis.
Methods: As in recent studies on colorectal cancer, a substantial improvement in prognostic 
evaluations has been provided by the histological analysis of the tumour invasive front; we 
therefore systematically analysed the tumour budding and poorly differentiated clusters in the 
invasive front of 47 Crohn’s disease-associated small bowel carcinomas collected through the 
Small Bowel Cancer Italian Consortium.
Results: Both tumour budding and poorly differentiated cluster analyses proved highly effective 
in prognostic evaluation of Crohn’s disease-associated small bowel carcinomas. In addition, they 
retained prognostic value when combined with two other parameters, i.e. glandular histology 
and stage I/II, both known to predict a relatively favourable small bowel carcinoma behaviour. 
In particular, association of tumour budding and poorly differentiated clusters in a combined 
invasive front score allowed identification of a minor subset of cancers [12/47, 25%] characterised 
by combined invasive front low grade coupled with a glandular histology and a low stage [I or II] 
and showing no cancer-related death during a median follow-up of 73.5 months.
Conclusions: The improved distinction of lower- from higher-grade Crohn’s disease-associated 
small bowel carcinomas provided by invasive front analysis should be of potential help in choosing 
appropriate therapy for these rare and frequently ominous neoplasms.
Key Words: Adenocarcinoma; grading; poorly differentiated cluster; tumour budding
1. Introduction
A previous study of small bowel carcinomas [SBCs] by our 
group found that glandular versus non-glandular histology 
and density of tumour-infiltrating T lymphocytes [TILs] were 
significant predictors of patient survival.1 The underlying 
immune-mediated predisposing disorder was also of prognostic 
value in SBCs; indeed, coeliac disease-associated cancers show 
a more favourable outcome than those associated with Crohn’s 
disease [CrD].2,3
CrD-associated SBC [CrD-SBC] as a whole showed poor prog-
nosis [5-year overall survival rate: 26–38%],3 and this is partly due to 
the advanced stage at diagnosis and to their often incidental finding 
at surgical resection for bowel stricture. The latter factor may imply 
suboptimal resections and/or inadequate lymph node dissection and, 
subsequently, the need for short-term re-intervention.4,5 However, 
we recently identified a smaller histological subset of CrD-SBCs, es-
pecially among those showing glandular differentiation, which was 
associated with less aggressive disease.1 The identification of factors 
which may improve the histopathological prediction of CrD-SBC 
prognosis is lacking, up till now.
Recent studies on colorectal and other gastrointestinal cancers have 
shown that careful analysis of tumour budding [Tb] and poorly differ-
entiated clusters [PDCs] at the tumour invasion front may substantially 
improve their prognostic evaluation.6–13 The aim of this study was to 
evaluate these histological parameters [Tb and PDCs] on a relatively 
large series of CrD-SBCs collected through the Small Bowel Cancer 
Italian Consortium, and hopefully to improve the prognostic charac-
terisation of this poorly known and relatively rare subset of cancers.
2. Materials and Methods
2.1. Study population
This retrospective study included 47 patients with primary non-ampullary 
CrD-SBCs, mostly from the ileum [n = 44], two from the jejunum, and 
one from the duodenum. The patients, some of whom have been partly 
studied in previous series,1,2,14 had surgical resection and complete sur-
vival data from 15 tertiary referral Italian inflammatory bowel disease 
centres participating in the Small Bowel Cancer Italian Consortium. 
Neuroendocrine neoplasms were excluded. This study was approved by 
the Ethics Committee of the San Matteo Hospital Foundation of Pavia.
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2.2. Histological evaluation
All available haematoxylin and eosin [H&E]-stained slides, including 
full-thickness sections of the tumour and encompassing the invasive 
front, were reviewed.
Tb and PDCs were analysed by two independent researchers [GA 
and AV] blinded to clinical and outcome data. An Eclipse Ci micro-
scope [Nikon] with a standard 22-mm diameter eyepiece [specimen 
area of 0.950 mm2 under an objective lens with a magnification of 
×20] was used, and the number of buds/PDCs was divided by 1.21 to 
achieve the number of buds per area of 0.785 mm2 as recommended 
for colorectal cancer.9
2.2.1. Definition and evaluation of Tb
A tumour bud is defined as a single tumour cell or a cell cluster 
of up to four tumour cells which develops from neoplastic glands. 
Tb was analysed along the invasive parts of the tumour using the 
hotspot method, which is considered to be the most useful method 
for assessing Tb in colorectal cancer.9 Initially, the invasive front of 
the tumour was screened using low magnification to find the areas 
with most Tb. For this purpose, cytokeratin 8–18 [monoclonal, 
clone EP17/EP30, Dako] immunohistochemistry was helpful in some 
challenging cases [i.e. glandular fragmentation, strong peritumoral 
inflammation] to allow a better visualisation of Tb-rich areas. Tb 
was assessed from several H&E areas, and the single field with the 
most budding was used for quantitation. The number of buds was 
counted in all cancers on H&E staining from a single field of view 
using ×200 total magnification [the hotspot method]. Following 
the International Tumour Budding Consensus Conference [ITBCC] 
group recommendation for colorectal cancer, we used a three-tier 
system: low budding [Tb1]: 0–4 buds; intermediate budding [Tb2]: 
5–9 buds; and high budding [Tb3]: 10 or more buds.9
2.2.2 Definition and evaluation of PDCs
PDCs were defined as clusters of ≥5 cancer cells that lacked 
a gland-like structure. The whole tumour was first scanned at 
low-power magnification to identify areas with the greatest 
number of PDCs at the invasive front. The number of PDCs 
in a single field of highest activity was then determined and 
graded as PDC1 [<5 PDCs], PDC2 [5–9 PDCs], or PDC3 
[≥10 PDCs] under an objective lens with a magnification of 
×20.8,15,16
Cases which would have been placed into different subgroups 
by the two investigators had their slides re-analysed by an expert 
gastrointestinal pathologist [ES], and a consensus was reached. In 
addition, a combined invasive front [CIF] grade was developed as 
high in the presence of grade 3 for either Tb or PDCs or both and as 
low in the remaining cases.
The following conventional histological parameters were also 
investigated: tumour histotype, World Health Organization [WHO] 
tumour grade [for the entire tumour], and TILs and all parameters 
required for Tumour, Node, Metastasis [TNM] staging.15 Tumour 
histotype was classified as: a] glandular, b] diffuse, c] mixed [glan-
dular plus diffuse], d] medullary, and e] non-medullary solid types, 
as previously described.1,18 Two cases resembling in part medullary 
cancers, one of which was Epstein Barr virus-positive and rein-
terpreted as lymphoepithelioma-like cancer,19 were omitted from 
this study, as recommended by Lugli et  al.,9 owing to technical 
difficulties in assessing Tb and PDC status. WHO tumour grade 
was based on the proportion of gland formation and categorised 
as grade 1 [well differentiated, >95%], grade 2 [moderately differ-
entiated, 50% to 95%], or grade 3 [poorly differentiated, 0% to 
49%]. In carcinomas with mucinous features, WHO grade, Tb, and 
PDCs were assessed in the area outside the mucinous component. 
Table 1. Histological classification and clinico-pathological features of the 47 Crohn’s disease-associated SBC cases
Histotype n [%] Male sex, Age at SBC diagnosis, P53 overexpression 
[>50%]
MSI/dMMR High TILs WHO grade, n [%]
n [%] median [25th-75th] n [%] n [%] n [%] 1 2 3
Glandular 24 [51.1] 18 [75] 59 [54.5–69] 14 [58.3] 6 [25] 9 [37.5] 6 [25] 17 [70.8] 1 [4.2]
Mixed 11 [23.4] 9 [81.8] 56 [46–68] 6 [54.5] 2 [18.2] 2 [18.2] 0 4 [36.4] 7 [63.6]
Diffuse 10 [21.3] 7 [70] 51 [39–59] 3 [30] 0 4 [40] 0 0 10 [100]
Solid 2 [4.2] 0 53 [44–62] 2 [100] 0 0 0 0 2 [100]
Total 47 [100] 34 [72] 57 [50–68] 25 [53.2] 8 [17] 15 [31.9] 6 [12.8] 21 [44.7] 20 [42.5]
All dMMR SBCs also showed MSI by molecular analysis.
SBC, small bowel cancer; WHO, World Health Organization; dMMR, defective mismatch repair; MSI, microsatellite instability; TIL, tumour-infiltrating 
lymphocyte.
WHO grade distribution among histotypes: p < 0.001. 
Table 2. Classification of 47 Crohn’s disease-associated SBC cases by invasive front-based grading systems
Histotype Tumour budding, n [%] Poorly differentiated clusters, n [%] Combined invasive front grade, n [%]
Tb1 Tb2 Tb3 PDC1 PDC2 PDC3 Low High
Glandular 12 [50] 4 [16.7] 8 [33.3] 13 [54.2] 6 [25] 5 [20.8] 14 [58.3] 10 [41.7]
Mixed 0 0 11 [100] 2 [18.2] 1 [9.1] 8 [72.7] 0 11 [100]
Diffuse 0 0 10 [100] 1 [10] 4 [40] 5 [50] 0 10 [100]
Solid 0 1 [50] 1 [50] 0 1 [50] 1 [50] 1 [50] 1 [50]
Total 12 [25.5] 5 [10.6] 30 [63.8] 16 [34] 12 [25.5] 19 [40.4] 15 [31.9] 32 [68.1]
SBC, small bowel cancer; Tb, tumour budding; PDC, poorly differentiated clusters; CIF, combined invasive front.
Tb and CIF grade distribution among histotypes: p < 0.001; PDC distribution among histotypes: p = 0.016.
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A tumour was classified as having high TIL density when the mean 
number of CD3-positive TILs was >15 per high-power field, as pre-
viously reported.2
For testing mismatch repair [MMR] protein deficiency, 
immunohistochemistry was performed using the standard 
streptavidin-biotin peroxidase procedure, with the following pri-
mary monoclonal antibodies against MLH1 [monoclonal, clone 
ES05, Dako], MSH2 [monoclonal, clone FE11, Dako], MSH6 
[monoclonal, clone EP49, Dako], and PMS2 [monoclonal, clone 
EP51, Dako]. Immunostaining of MMR proteins in tumour cells 
was evaluated as proficient [MMRp: retained expression] or defi-
cient [MMRd: absent expression]; only tumours showing absence of 
nuclear staining of all neoplastic cells in the presence of an internal 
positive control [intra-tumour stromal and inflammatory cells or 
non-tumour mucosa] were considered deficient.2 In parallel, micro-
satellite instability [MSI] molecular analysis was performed as pre-
viously reported.2
Finally, we searched for a correlation between invasive 
front markers and KRAS, NRAS, and PIK3CA mutations in 
24 CrD-SBC cases, whose gene mutation analysis was avail-
able from a previous investigation, as already described.2 In 
addition, immunohistochemistry for p53 [monoclonal, clone 
DO7, Dako] was performed in all cases; a CrD-SBC was con-
sidered p53-positive when more than 50% of tumour cells 
showed strong nuclear p53 immunoreactivity, in line with 
previous studies.2
A B
C D
Figure 1. [A] A glandular Crohn’s disease-associated small bowel carcinoma [CrD-SBC] showing grade 1 tumour budding [Tb1] and grade 1 poorly differentiated 
clusters [PDC1] at the tumour invasive front [on the right] [haematoxylin and eosin; original magnification, 200x]. [B] A mixed-type CrD-SBC with grade 3 PDCs 
[arrows; haematoxylin and eosin; original magnification, 200x]. [C], [D] A glandular CrD-SBC showing grade 3 Tb [arrows; C, haematoxylin and eosin; D, pan-
cytokeratin immunostaining; original magnification, 200x].
Table 3. Distribution of Tb, PDC and CIF scores among the 47 Crohn’s disease-associated SBC cases classified according to pT and 
AJCC stage.
Grading system Cases, n [%] pT, n [%] p-value Stage, n [%] p-value
pT1 pT2 pT3 pT4 I II III IV
Tb Tb1 12 [25.5] 2 [16.7] 4 [33] 5 [41.7] 1 [8.3] 0.001 6 [50] 5 [41.7] 1 [8.33] 0 <0.001
Tb2 5 [10.7] 0 0 2 [40] 4 [60]  0 3 [60] 2 [40] 0  
Tb3 30 [63.8] 0 0 16 [53.3]  14 [46.7]  0 11 [36.7] 13 [43.3] 6 [20]  
PDC PDC1 16 [34.1] 2 [12.5] 4 [25] 7 [43.7] 3 [18.8] 0.016 6 [37.5] 6 [37.5] 4 [25] 0 0.002
PDC2 12 [25.5] 0 0 8 [66.7] 4 [33.3] 0 8 [66.7] 2 [16.7] 2 [16.7]
PDC3 19 [40.4] 0 0 8 [42.1] 11 [57.9] 0 5 [26.3] 10 [52.6] 4 [21.1]
CIF 
grade
CIF low grade 15 [31.9] 2 [13.3] 4 [26.7] 6 [40] 3 [20] 0.002 6 [40] 8 [53.3] 1 [6.7] 0 <0.001
CIF high grade 32 [68.1] 0 0 17 [53.1] 15 [46.9] 0 11 [34.4] 15 [46.9] 6 [18.7]
SBC, small bowel carcinoma; Tb, tumour budding; PDC, poorly differentiated clusters; CIF, combined invasive front; pT, extent of the tumour into the layers 
of the wall of the small intestine [according to the 8th edn, AJCC TNM staging system]; AJCC, American Joint Committee on Cancer; TNM, Tumour, Node, 
Metastasis.
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2.3. Statistical analysis
We used Stata 15.1 [StataCorp, College Station, TX, USA] for all 
computations. We considered a two-sided p-value < 0.05 as statis-
tically significant. We did not apply multiple endpoints correction 
for the exploratory subgroup analyses. We described data with the 
median and 25th–75th percentiles if continuous, and with counts 
and percentages if categorical. We compared them between groups 
with the Kruskall-Wallis test and Fisher’s exact test, respectively. We 
computed median follow-up with the reverse Kaplan-Meier method. 
We analysed cancer-specific mortality by computing the mortality 
rate per 100 person-years, plotting the Kaplan-Meier survival curves 
and assessing the risk of dying for a series of candidate risk factors 
with the hazard ratio [HR] and 95% confidence interval [CI] derived 
from a Cox model. We checked the proportional hazard assumption 
with a test based on residuals. We computed the Harrell’s c statistic 
for discrimination [the closer to 1, the better, the closer to 0.5, the 
worse]. Given the low number of deaths, we did not fit multivariable 
survival models.
3. Results
The histological classification of 47 CrD-SBCs and pertinent distri-
bution of some clinico-pathological features are reported in Table 1. 
A general predominance of male sex and a median age of 57 years 
at SBC diagnosis are worth of note. Fifteen cases showed high TIL 
density, only eight harboured defective MMR [including seven cases 
with loss of MLH1/PMS2 and one case showing isolated loss of 
MSH6], and p53 overexpression was observed in 53.2% of CrD-
SBCs without significant difference among histotypes. KRAS, NRAS, 
and PIK3CA mutations were found in three [12.5%], one [4%], and 
Table 4. Cancer-specific survival of 45 Crohn’s disease-associated SBCs classified according to their invasion front pattern and other 
predictive parameters.
Parameter Cases n Deaths n [%] Rate per 100  
person-years [95% CI]
HR [95% CI] p-value  
[Cox]
Harrell’s c  
[95% CI]
Tumour  
budding
Tb1 11 1 [9.1] 1.33 [0.19–9.44] 1 <0.001 0.68 [0.59–0.77]
Tb2 5 2 [40] 20.25 [5.06–80.97] 10.6 [0.95–118.7]
Tb3 29 20 [68.9] 25.18 [16.24–39.03] 14.72 [1.95–111.18]
PDC PDC1 15 3 [20] 3.69 [1.19–11.43] 1 0.004 0.69 [0.58–0.80]
PDC2 12 8 [66.7] 23.84 [11.92–47.67] 4.88 [1.29–18.46]
PDC3 18 12 [66.7] 24.23 [13.76–42.67] 5.94 [1.67–21.15]
CIF grade low 14 2 [14.3] 2.45 [0.61–9.78] 1 <0.001 0.66 [0.57–0.75]
high 31 21 [67.7] 25.38 [16.55–38.92] 8.27 [1.91–35.90]
WHO G1 5 0 0 not evaluable [-∞] 0.001 0.67 [0.56–0.78]
G2 20 8 [40] 10.14 [5.07–20.27] 1
G3 20 15 [75] 29.97 [18.07–49.71] 2.08 [0.88–4.91]
Histotype glandular 22 5 [22.7] 4.59 [1.91–11.03] 1 <0.001 0.68 [0.58–0.78]
non-glandular 23 18 [78.3] 32.38 [20.4–51.39] 5.02 [1.85–13.63]
TILs high 15 4 [26.7] 5.62 [2.11–14.98] 1 0.027 0.60 [0.50–0.70]
low 30 19 [63.3] 20.36 [12.99–31.92] 3.01 [1.02–8.92]
Stage I 5 0 0 not evaluable [-∞] <0.001 0.80 [0.72–0.87]
II 19 6 [31.6] 5.81 [2.61–12.94] 1
III 15 11 [73.3] 50.24 [27.82–90.72] 8.29 [2.51–27.31]
IV 6 6 [100] 81.39 [36.57–181.18] 13.65 [3.67–50.83]
SBC, small bowel cancer; Tb, tumour budding; PDC, poorly differentiated clusters; CIF, combined invasive front; TILs, tumour-infiltrating lymphocytes; HR, 
hazard ratio; CI: confidence interval; WHO, World Health Organization.
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Figure 2. Kaplan-Meier survival estimates on the 45 Crohn’s disease-associated small bowel carcinomas [CrD-SBCs] by stage [A] and histotype [B].
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two [8%], respectively, out of 24 cases tested. Glandular-type can-
cers were mostly well-to-moderately differentiated according to the 
WHO grading system.
The histological analysis of tumour invasion front parameters 
[Table 2 and Figure 1] showed a significant association [p < 0.001] be-
tween histotypes and either Tb or PDC grades, with a predominance 
of Tb1 [50%] and PDC1 [52%] among glandular-type cases, as well 
as of Tb3 [100%] and PDC3 [62%] among diffuse/mixed cancers. 
As for both Tb and PDC, survival analysis gave poor separation [not 
significant p-values] of the relatively few grade 2 cases from the re-
maining grades, a two-tiered combined invasive front [CIF] grade was 
developed where grade 3 cases for either Tb or PDC or both defined 
CIF-high grade and all the remaining cases formed CIF-low grade. All 
diffuse and mixed tumours were placed in the CIF-high grade group, 
in contrast to a minority [10/24, 42%] of glandular cases. In Table 
3, data on depth of tumour invasion [pT] and AJCC stage as a func-
tion of Tb, PDC, and CIF grade are reported: an overall correlation 
was found between each of the three invasive front grading systems 
and invasion/stage parameters. Importantly, Tb, PDC, or CIF grade 
were significantly associated with lymph node metastases [p = 0.001, 
p = 0.023, and p < 0.001, respectively, with increasing rate of lymph 
node metastases across grades]. On the other hand, no association be-
tween invasive front markers and KRAS, NRAS, PIK3CA mutations, 
p53 overexpression, or MMR/MSI status was found.
Two patients died peri-operatively; the remaining 45 patients 
were followed up for a median of 85 [25th-75th percentiles: 31–121] 
months, and their cancer-specific survival data are reported in Table 
4. As expected, stage and histotype proved highly associated with sur-
vival [Figure 2], and high TILs, found in 27% of cases, and high WHO 
grade, with only very few grade 1 cases, were less contributive. Both 
Tb and PDC invasive front analyses gave effective patient prognos-
tication; in particular, their combination into a CIF grade separated 
14 low-grade from 31 high-grade SBC patients with highly divergent 
outcomes [Figure 3 and Table 4]. In addition, when CIF grade was 
applied to the 22 glandular histology cases [by themselves showing 
significantly better survival than 23 non-glandular cases], 13 CIF-low 
as distinguished from nine CIF-high grade tumours were identified, 
with a trend for divergent outcomes [HR = 6.54, 95% CI: 0.73–58.6, 
p = 0.054], despite the limited number of available cases. CIF grade 
also gave significant results when applied to 24 stage I+II tumours, 
thus separating 13 low- [12 of which present in the CIF-low grade 
glandular group] from 11 high-grade cases, with significantly dif-
ferent outcomes [HR = 7.78, 95% CI: 0.90–67.3, p = 0.027]. Indeed, 
no cancer-related death was observed, during a median follow-up of 
73.5 months, among the 12 patients with CrD-SBC showing CIF-low 
grade, glandular structure, and stage I or II. Of interest, six [50%] of 
such tumours also showed high TILs, and three were MMRd.
4. Discussion
In this study of an expanded series of CrD-SBCs we confirmed the 
favourable prognostic influence of glandular structure [i.e. glandular 
histotype] in comparison with its loss to form diffuse or mixed can-
cerous growths, as already suggested in a previous investigation of 
a smaller series.1 In addition to this architectural evaluation on the 
whole cancer tissue, we found that selective investigation of the tu-
mour invasive front for foci of Tb and/or PDCs substantially im-
proved separation of more from less aggressive cases. Moreover, a 
significant association of Tb and PDC with lymph node metastases 
was found. In particular, invasive front analysis was effective, in 
glandular type CrD-SBCs, in identifying cases with numerous foci 
of cell dissociation or structural dedifferentiation [high-grade Tb or 
PDCs], which were significantly coupled with survival shortening 
in comparison with those with low-CIF grade [low-to-intermediate 
grade Tb and PDCs]. The use of a novel CIF two-tier grading system, 
which encompasses both Tb and PDC, renders this system easier to 
apply compared with the separate evaluation of Tb and PDC.
Our results extend to CrD-SBC the prognostic value of Tb and 
PDC evaluation, so far mainly documented for colorectal cancer 
[predominantly gland-forming, usual type adenocarcinoma]. 
Furthermore, we show that the usefulness of CIF grade is restricted 
to the SBC glandular subset, a finding in keeping with recent obser-
vations on gastric cancer.20 It appears that both processes involved 
in loss of structural differentiation, one occurring massively within 
the neoplasm as a whole, resulting in the diffuse and mixed tumour 
histotypes, and the other selectively acting at its invasive front [i.e. 
the high-grade Tb or PDCs], are strongly associated with a worse 
patient outcome. In other words, persistence, even at the invasive 
front, of the ‘canonical’ glandular-type structure marks a relatively 
less aggressive subset of CrD-SBCs, mostly non-metastatic and with 
a limited invasiveness.
It should be noted that loss of cellular/glandular differentiation 
to form ‘poorly cohesive’ tumours has long been recognised among 
gastric cancers and suggested to worsen patient prognosis.21–23 Recent 
molecular studies have stressed that diffuse desmoplastic cancers of 
the stomach, pancreas, and colon likely represent the histological 
counterpart of the so-called epithelial-to-mesenchymal transition op-
erative in such cancers, with severe prognostic impact.24–29 It seems 
clear, especially from recent studies on colorectal carcinoma, that 
cancer investigation at its invasive front may capture an otherwise 
unapparent cancer proneness to cell dissociation and invasion, thus 
predicting worse postoperative behaviour.6–9,30 From our evaluation, 
it appears that the same phenomenon occurs in CrD-SBCs, which may 
add further information to stage assessment of surgical specimens.
High TIL density was associated with favourable survival, also 
among CrD-SBC; however, TIL assessment proved less effective in 
CrD-SBCs than in coeliac disease-associated SBCs,2 being present 
in a smaller fraction of cases. TILs-rich medullary-type cancers, 
including the Epstein Barr virus-positive LEC with medullary-like 
histology,19 are known by themselves to generally display a more 
favourable outcome,31–33 thus overcoming the technical difficulty for 
Tb and PDC assessment reported in this rare cancer type.
In conclusion, analysis of tumour cell dissociation/
de-differentiation markers at the invasive front, such as Tb and 
PDCs, may improve the identification of highly malignant cancers 
and allow their separation from a minority of less aggressive neo-
plasms, with potential therapeutic implications. Importantly, simi-
larly to colorectal cancer, tumour invasive front markers might help 
in selecting high-risk CrD-SBC patients for adjuvant chemotherapy 
or additional surgery.33–37
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